Anesthesia management for pediatric day surgery requires rapid onset, accurate control, and predictable recovery. Remimazolam is an ultrashort-acting benzodiazepine with esterase-dependent metabolism. Current pediatric evidence is based primarily on small observational studies with methodological limitations. Data for infants under 2 years of age and long-term neurodevelopmental outcomes are virtually lacking. Remimazolam shows promise, but its use must be cautious and limited to carefully selected scenarios. Until robust randomized controlled trials are available, it is not suitable for widespread use.